AI Stock Memo: ALMS - Alumis - RankAlpha

ALMS

AI Memo

Alumis

As of 2026-06-06/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-06-06 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q1 2026 results kept the lead asset on track • 2026-05-14

Expected move: +1%

Biggest risk

Bears will focus on binary clinical and regulatory risk: if SLE disappoints, if the NDA slips, or if safety/tolerability or launch execution deteriorates, the equity can re-rate sharply because there is still no commercial earnings cushion [#SEC-8K-2026-05-14].

Invalidation

Break below $12 or thesis failure.

What would change my mind?

Bulls can point to the Phase 3 psoriasis win, the favorable safety profile, the 4Q26 NDA path, and the 3Q26 SLE readout as a sequence of value-creating catalysts; secondary post-print coverage also says Chardan, Wells Fargo, and Guggenheim raised targets to $40, $51, and $34, respectively, after Q1 [#SEC-8K-2026-05-14] [#PR-EARNINGS-2026-05-29].

Research note

Recommendation

—

Confidence

medium

As of

2026-06-06

Base target

$30

p=50%

Bull target

$45

p=25%

Bear target

$12

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Unified TYK2 franchise expansion
Bulls can point to the Phase 3 psoriasis win, the favorable safety profile, the 4Q26 NDA path, and the 3Q26 SLE readout as a sequence of value-creating catalysts; secondary post-print coverage also says Chardan, Wells Fargo, and Guggenheim raised targets to $40, $51, and $34, respectively, after Q1 [#SEC-8K-2026-05-14] [#PR-EARNINGS-2026-05-29].
The packet's analyst target summary centers on $38 versus a $19.06 anchor, implying substantial upside if the TYK2 story fully de-risks.

BearKey bullets

Psoriasis NDA timing and FDA feedback may slip; any CRL or label friction would hit the valuation hard.
Safety/tolerability concerns or competitive TYK2/psoriasis data could compress the premium multiple.
The SLE Phase 2b readout could miss or show weaker-than-hoped durability, undermining the pipeline-broadening case.

WatchKey bullets

Q1 2026 results kept the lead asset on track

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $30 (p=50%)

Bull/Bear spread: +51% / -60%

Vs latest close: Bull +51% · Base +1% · Bear -60%

Scenario probabilities

Bull Target: $45 (p=25%)Base Target: $30 (p=50%)Bear Target: $12 (p=25%)

Commentary

Lean positive on the long-term TYK2 package but cautious on timing. The primary-source 8-K is constructive on clinical efficacy, cash runway, and upcoming milestones, yet the deterministic prior is negative across the next 5d-120d window, which argues for a monitoring stance rather than a chased-up breakout call. Secondary post-print analyst coverage was upbeat, but that only partially offsets the binary SLE/NDA risk and thin near-term commercialization evidence [#SEC-8K-2026-05-14] [#PR-EARNINGS-2026-05-29].

As of 2026-06-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Unified TYK2 franchise expansion

Scenarios

Bull Target (Scenario probability)

$45 / p=25% prob

Base Target (Scenario probability)

$30 / p=50% prob

Bear Target (Scenario probability)

$12 / p=25% prob

Price $30 as of 2026-07-08

Nearest Scenario: Base (∆ 1%)

Targets vs latest close: Bull +51% · Base +1% · Bear -60%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-14
Q1 2026 results kept the lead asset on track
The May 14 company update reaffirmed positive Phase 3 psoriasis data, a favorable safety/tolerability profile, and $569.5M of cash/cash equivalents/marketable securities that management says funds operations into 4Q27 [#SEC-8K-2026-05-14].
Prob 90.00% • Move 10.00% • Priced-in 80.00%
EVENT2026-09-15
Potentially pivotal SLE topline in 3Q 2026
The LUMUS Phase 2b systemic lupus erythematosus readout remains the key franchise-broadening event beyond psoriasis and is still guided for 3Q26 [#SEC-8K-2026-05-14].
Prob 60.00% • Move 25.00% • Priced-in 35.00%
EVENT2026-11-15
Psoriasis NDA filing targeted for 4Q 2026
Management stayed on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q26 after the positive Phase 3 package [#SEC-8K-2026-05-14].
Prob 75.00% • Move 18.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Unified TYK2 franchise expansion
2026-10-31
Alumis said it is evaluating additional indications under a unified TYK2 franchise strategy and expects more updates later in 2026, which could widen the long-duration market opportunity if the current data package holds [#SEC-8K-2026-05-14].
Prob 45% • Move 12% • Priced-in 25%

Risks

Psoriasis NDA timing and FDA feedback may slip; any CRL or label friction would hit the valuation hard.
Safety/tolerability concerns or competitive TYK2/psoriasis data could compress the premium multiple.
The SLE Phase 2b readout could miss or show weaker-than-hoped durability, undermining the pipeline-broadening case.
The company is still pre-commercial with no operating revenue cushion, so clinical spend and launch prep can keep cash burn elevated despite the 4Q27 runway.

Peers

Symbol	Summary
ARQT	Dermatology-biotech comp with more commercial footing; useful for framing how psoriasis assets trade once clinical validation starts translating into launch expectations.
IDYA	Similarly sized clinical biotech where valuation is still dominated by discrete readouts and milestone timing rather than current revenue.
IRON	Near-cap biotech comp whose share price remains sensitive to trial timing, binary data risk, and capital-markets access.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-06-06